<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762319</url>
  </required_header>
  <id_info>
    <org_study_id>SIOGMVA002</org_study_id>
    <nct_id>NCT01762319</nct_id>
  </id_info>
  <brief_title>Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol</brief_title>
  <official_title>Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding (AUB) Using Sublingual Misoprostol 200 Mcg: A Randomized, Double Blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abnormal uterine bleeding is common in Thai women. Fractional curettage is an diagnostic
      procedure of this condition. Traditionally, fractional curettage is performed under local
      anesthesia such as paracervical nerve block or intravenous meperidine.

      Cervical dilatation using &quot;metal cervical dilator&quot; is a common method prior to perform
      fractional curettage. However, complication from this procedure can be occurred frequently,
      for example, uterine perforation, false tract formation and laceration of cervix.

      Misoprostol is a prostaglandin E1 analogue which is commonly used in obstetrics and
      gynecology. Misoprostol transforms cervical component causing cervical ripening. This is very
      helpful for transcervical procedure because cervical dilatation is usually omitted. It can be
      prescribed in many route and sublingual route is the most effectiveness. Moreover, WHO
      supports the use of misoprostol in obstetrics and gynecology practice.

      The hypothesis of this study is that &quot;Misoprostol 200 micrograms sublingually is effective
      for cervical ripening before performing fractional curettage in patients with abnormal
      uterine bleeding&quot; Double blind randomised controlled trial was performed using 26 patients in
      each group.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of 200 microgram Misoprostol for cervical ripening prior to performing fractional curettage in patients with abnormal uterine bleeding</measure>
    <time_frame>1 Year</time_frame>
    <description>an efficacy of sublingual misoprostol in this study was dilatation of uterine cervix which was measured by a diameter of MVA cannula in millimeters.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Abnormal Uterine Bleeding Unrelated to Menstrual Cycle</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mcg Misoprostol SL 1 hour prior to fractional curettage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin B6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mg Vitamin B6 SL 1 hr prior to fractional curettage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B6</intervention_name>
    <arm_group_label>Vitamin B6</arm_group_label>
    <other_name>Besix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  thai women at the age over 35 years old

          -  presenting with abnormal uterine bleeding and have a plan to perform fractional
             curettage

        Exclusion Criteria:

          -  uterine anomalies

          -  pregnancy

          -  pelvic inflammatory disease

          -  uncontrolled medical or psychological conditions

          -  known cases of gynecological diseases such as gynecological malignancies, abnormal pap
             smear

          -  Prostaglandin allergy

          -  Contraindicate to prostaglandin: asthma, mitral valve stenosis, glaucoma, sickle cell
             anemia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Korakot Sirimai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Korakot Sirimai, Dr.</last_name>
    <phone>(66)81-6140655</phone>
    <email>ksirimai@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Korakot Sirimai, Dr.</last_name>
      <phone>(66)81-6140655</phone>
      <email>ksirimai@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Korakot Sirimai, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tripop Lertbunnaphong, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Mittal S, Sehgal R, Aggarwal S, Aruna J, Bahadur A, Kumar G. Cervical priming with misoprostol before manual vacuum aspiration versus electric vacuum aspiration for first-trimester surgical abortion. Int J Gynaecol Obstet. 2011 Jan;112(1):34-9. doi: 10.1016/j.ijgo.2010.07.035. Epub 2010 Nov 26.</citation>
    <PMID>21112054</PMID>
  </reference>
  <reference>
    <citation>Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009 Summer;2(3):159-68.</citation>
    <PMID>19826573</PMID>
  </reference>
  <reference>
    <citation>Cooper NA, Smith P, Khan KS, Clark TJ. Does cervical preparation before outpatient hysteroscopy reduce women's pain experience? A systematic review. BJOG. 2011 Oct;118(11):1292-301. doi: 10.1111/j.1471-0528.2011.03046.x. Epub 2011 Jul 29. Review.</citation>
    <PMID>21797959</PMID>
  </reference>
  <reference>
    <citation>Saxena P, Salhan S, Sarda N. Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. Contraception. 2003 Mar;67(3):213-7.</citation>
    <PMID>12618256</PMID>
  </reference>
  <reference>
    <citation>Saxena P, Salhan S, Sarda N. Sublingual versus vaginal route of misoprostol for cervical ripening prior to surgical termination of first trimester abortions. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):109-13. Epub 2005 Sep 1.</citation>
    <PMID>16139942</PMID>
  </reference>
  <reference>
    <citation>Caliskan E, Filiz T, Yucesoy G, Coskun E, Vural B, Corakci A. Sublingual versus vaginal misoprostol for cervical ripening PRIOR TO manual vacuum aspiration under local anaesthesia: a randomized study. Eur J Contracept Reprod Health Care. 2007 Dec;12(4):372-7.</citation>
    <PMID>17853158</PMID>
  </reference>
  <reference>
    <citation>Saha SP, Bhattacharjee N, Baru G. Vaginal Misoprostol for Cervical Priming before Gynaecological Procedures on Non Pregnant Women. Int J Health Sci (Qassim). 2007 Jul;1(2):185-93.</citation>
    <PMID>21475427</PMID>
  </reference>
  <reference>
    <citation>Boonyarangkul A, Leksakulchai O. Comparison of level of pain between using manual vacuum aspiration and sharp curettage in management of abnormal uterine bleeding. J Med Assoc Thai. 2011 Dec;94 Suppl 7:S57-61.</citation>
    <PMID>22619908</PMID>
  </reference>
  <reference>
    <citation>Tansathit T, Chichareon S, Tocharoenvanich S, Dechsukhum C. Diagnostic evaluation of Karman endometrial aspiration in patients with abnormal uterine bleeding. J Obstet Gynaecol Res. 2005 Oct;31(5):480-5.</citation>
    <PMID>16176522</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

